Derma Sciences to Hold Third Quarter Financial Results Conference Call on November 11
November 03 2011 - 8:00AM
Business Wire
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and
pharmaceutical company focused on advanced wound care announced
today that the Company will hold a conference call on November 11,
2011 to discuss the financial results for the third quarter ended
September 30, 2011. In addition, management will provide a business
update and a discussion on recent and upcoming milestones.
The conference call is scheduled to begin at 11:00 a.m. EST
(Eastern Standard Time). The results will be released before the
opening of the market that same day.
To access the conference call, U.S.-based listeners should dial
888-563-6275 and international listeners should dial 706-634-7417.
All listeners should provide the following passcode: 21893992.
Individuals interested in listening to the live conference call
via the Internet may do so by logging on to the Company’s website,
www.dermasciences.com. Listeners should log in 15 minutes prior to
the start of the call to test their browsers and register for the
webcast.
Following the end of the conference call, a replay will be
available through November 18, 2011, and can be accessed by dialing
(855) 859-2056 within the U.S. or (404) 537-3406 outside of the
U.S. All listeners should provide the following passcode: 21893992.
The webcast will also be available for 30 days.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three
segments of the wound care marketplace: pharmaceutical wound care
products, advanced wound care dressings and traditional dressings.
Derma Sciences has successfully completed the treatment phase of a
Phase 2 clinical trial in diabetic foot ulcer healing with DSC127,
a novel pharmaceutical drug under development for accelerated wound
healing and scar reduction. Its MEDIHONEY® product is the leading
brand of honey-based dressings for the management of wounds and
burns. The product has been shown to be effective in a variety of
indications, and was the focus of a positive large-scale,
randomized controlled trial involving 108 subjects with leg ulcers.
Other novel products introduced into the $14 billion global wound
care market include XTRASORB® for better management of wound
exudate, and BIOGUARD® for infection prevention.
For more information please visit www.dermasciences.com.
Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From May 2023 to May 2024